Kendall B. Wallace
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kendall B. Wallace has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Hans Wj. Marquardt
Experimental and Clinical Toxicology University of Hamburg Medical School Hambug, Germany
4 shared publications - Paulo Jorge Oliveira
Interdisciplinary Centre of Marine and Environmental Research (CIIMAR/CIMAR), University of Porto
4 shared publications - Carlos Marques Palmeira
Department of Life Sciences, Faculty of Sciences and Technology, University of Coimbra, 3000-456 Coimbra, Portugal
3 shared publications - Colin Berry
Prof. (emeritus) of Pathology, Queen Mary, London, UK
3 shared publications - Corrado Lodovico Galli
Università degli Studi di Milano
3 shared publications - Gio Batta Gori
Regulatory Toxicology and Pharmacology, Bethesda, MD, USA
3 shared publications
Latest Publications
- 28 March 2022
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 442, 116003
Molnupiravir; molecular and functional descriptors of mitochondrial safety
- 28 March 2022
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 442, 116003
Molnupiravir; molecular and functional descriptors of mitochondrial safety
- 1 December 2021
- Published by Elsevier in Toxicology
- Vol. 464, 152997
Transcriptional effects of binary combinations of PFAS in FaO cells
- 1 December 2021
- Published by Elsevier in Toxicology
- Vol. 464, 152997
Transcriptional effects of binary combinations of PFAS in FaO cells
- 2 November 2021
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 433, 115783
Remdesivir; molecular and functional measures of mitochondrial safety
- 2 November 2021
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 433, 115783
Remdesivir; molecular and functional measures of mitochondrial safety
- 4 June 2020
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 20 (6) , 557-570
Disruption of the Keap1/Nrf2-Antioxidant Response System After Chronic Doxorubicin Exposure In Vivo
Doxorubicin (DOX) is a widely prescribed anthracycline antineoplastic drug for treating human solid tumors and leukemias. However, DOX therapy is limited by a cumulative, dose-dependent, and irreversible cardiomyopathy that occurs with repeated administration. Presumably, a pivotal initiating event of DOX-induced cardiotoxicity is the production of reactive oxygen species (ROS) and oxidation of lipids, DNA, and proteins. We recently identified activation of the Keap1/Nrf2-antioxidant response system—a major cellular defense mechanism against such oxidative stress—as an important response to acute DOX exposure in vitro. In the present study, we address the hypothesis that dysregulation of this pathway in cardiac tissue is also manifested in vivo following chronic DOX administration. Male, Sprague–Dawley rats received 6 weekly injections of 2 mg/kg (s.c.) DOX or saline followed by a 5-week drug-free period prior to analysis of cardiac tissue transcripts and proteins. In contrast to in vitro findings, the Keap1/Nrf2-antioxidant response system was suppressed in hearts of DOX-treated animals and consistent with the observed decrease in protein abundance for Nrf2 and PGAM5, both of which are substrates for Keap1. Although this shift in Keap1/Nrf2 suppresses the antioxidant pathway, the concurrent loss of PGAM5 could function as a signal for disposal of damaged mitochondria from the cell, thus removing the source of ROS. These findings identify the Keap1/Nrf2 and Keap1/PGAM5 pathways as important responses to DOX-induced cardiac injury in vivo; disruption of this system for mitochondrial hormesis may be an important contributing factor to cardiotoxicity after chronic drug administration.
- 4 June 2020
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 20 (6) , 557-570
Disruption of the Keap1/Nrf2-Antioxidant Response System After Chronic Doxorubicin Exposure In Vivo
Doxorubicin (DOX) is a widely prescribed anthracycline antineoplastic drug for treating human solid tumors and leukemias. However, DOX therapy is limited by a cumulative, dose-dependent, and irreversible cardiomyopathy that occurs with repeated administration. Presumably, a pivotal initiating event of DOX-induced cardiotoxicity is the production of reactive oxygen species (ROS) and oxidation of lipids, DNA, and proteins. We recently identified activation of the Keap1/Nrf2-antioxidant response system—a major cellular defense mechanism against such oxidative stress—as an important response to acute DOX exposure in vitro. In the present study, we address the hypothesis that dysregulation of this pathway in cardiac tissue is also manifested in vivo following chronic DOX administration. Male, Sprague–Dawley rats received 6 weekly injections of 2 mg/kg (s.c.) DOX or saline followed by a 5-week drug-free period prior to analysis of cardiac tissue transcripts and proteins. In contrast to in vitro findings, the Keap1/Nrf2-antioxidant response system was suppressed in hearts of DOX-treated animals and consistent with the observed decrease in protein abundance for Nrf2 and PGAM5, both of which are substrates for Keap1. Although this shift in Keap1/Nrf2 suppresses the antioxidant pathway, the concurrent loss of PGAM5 could function as a signal for disposal of damaged mitochondria from the cell, thus removing the source of ROS. These findings identify the Keap1/Nrf2 and Keap1/PGAM5 pathways as important responses to DOX-induced cardiac injury in vivo; disruption of this system for mitochondrial hormesis may be an important contributing factor to cardiotoxicity after chronic drug administration.
- Open Access
Drug-Induced Mitochondrial Toxicity in the Geriatric Population: Challenges and Future Directions
Mitochondrial function declines with age, leading to a variety of age-related diseases (metabolic, central nervous system-related, cancer, etc.) and medication usage increases with age due to the increase in diseases. Drug-induced mitochondrial toxicity has been described for many different drug classes and can lead to liver, muscle, kidney and central nervous system injury and, in rare cases, to death. Many of the most prescribed medications in the geriatric population carry mitochondrial liabilities. We have demonstrated that, over the past decade, each class of drugs that demonstrated mitochondrial toxicity contained drugs with both more and less adverse effects on mitochondria. As patient treatment is often essential, we suggest using medication(s) with the best safety profile and the avoidance of concurrent usage of multiple medications that carry mitochondrial liabilities. In addition, we also recommend lifestyle changes to further improve one’s mitochondrial function, such as weight loss, exercise and nutrition.
Open AccessDrug-Induced Mitochondrial Toxicity in the Geriatric Population: Challenges and Future Directions
Mitochondrial function declines with age, leading to a variety of age-related diseases (metabolic, central nervous system-related, cancer, etc.) and medication usage increases with age due to the increase in diseases. Drug-induced mitochondrial toxicity has been described for many different drug classes and can lead to liver, muscle, kidney and central nervous system injury and, in rare cases, to death. Many of the most prescribed medications in the geriatric population carry mitochondrial liabilities. We have demonstrated that, over the past decade, each class of drugs that demonstrated mitochondrial toxicity contained drugs with both more and less adverse effects on mitochondria. As patient treatment is often essential, we suggest using medication(s) with the best safety profile and the avoidance of concurrent usage of multiple medications that carry mitochondrial liabilities. In addition, we also recommend lifestyle changes to further improve one’s mitochondrial function, such as weight loss, exercise and nutrition.
- 1 February 2019
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 124, 450-461
Single nanomolar doxorubicin exposure triggers compensatory mitochondrial responses in H9c2 cardiomyoblasts
- 1 February 2019
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 124, 450-461
Single nanomolar doxorubicin exposure triggers compensatory mitochondrial responses in H9c2 cardiomyoblasts
- Open Access
- 11 July 2018
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 97, A1-A3
Obfuscating transparency?
- 11 July 2018
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 97, A1-A3
Open AccessObfuscating transparency?
- 1 August 2017
- Published by Elsevier in Toxicology
- Vol. 388, 7-8
Future perspective of butter flavorings-related occupational lung disease
- 1 August 2017
- Published by Elsevier in Toxicology
- Vol. 388, 7-8
Future perspective of butter flavorings-related occupational lung disease
- 1 December 2016
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 82, A1-A2
Whither the impending european regulation of presumed endocrine disruptors?
- 1 December 2016
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 82, A1-A2
Whither the impending european regulation of presumed endocrine disruptors?
- 1 September 2016
- Published by Elsevier in Toxicology
- Vol. 371, 12-16
Upholding science in health, safety and environmental risk assessments and regulations
- 1 September 2016
- Published by Elsevier in Toxicology
- Vol. 371, 12-16
Upholding science in health, safety and environmental risk assessments and regulations